Every material Form 8-K Liquidia filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Liquidia Technologies, a subsidiary of Liquidia Corporation, signed an Eighth Amendment on November 22, 2024 extending the lease on its Durham, North Carolina headquarters by 62 months. The extension runs from November 1, 2026 to December 31, 2031, with base rent starting at $136,224.48 per month. The filing describes this as a routine lease amendment with no stated effect on Liquidia's financial results.
Lease extension of 62 months, commencing November 1, 2026 and expiring December 31, 2031
Monthly base rent rises from $136,224.48 in the first 12 months to $157,907.66 for the final two months
No base rent is owed for the first two calendar months of the extension period, provided the tenant is not in default
Tenant has a five-year renewal option, with notice due 12 to 18 months before expiration
Liquidia reported third quarter 2024 revenue of $4.4 million, up from $3.7 million a year earlier, while its net loss widened to $23.2 million, or $0.30 per share, from $15.8 million, or $0.24 per share. Operating expenses rose sharply, with general and administrative expenses up 91% to $20.2 million, though a $7.2 million gain on debt extinguishment reduced the net loss. Cash and cash equivalents were $204.4 million as of September 30, 2024, and the company said its recent capital raises strengthened the balance sheet.
Revenue was $4.4 million for the quarter ended September 30, 2024, compared with $3.7 million a year earlier, mainly from the Sandoz promotion agreement.
Net loss was $23.2 million, or $0.30 per share, compared with a net loss of $15.8 million, or $0.24 per share, a year earlier.
General and administrative expenses rose 91% to $20.2 million, and research and development expenses rose 60% to $11.9 million.
Cash and cash equivalents totaled $204.4 million at September 30, 2024, up from $83.6 million at December 31, 2023.
On October 2, 2024, Liquidia Technologies, a wholly owned subsidiary of Liquidia Corporation, amended its license with Pharmosa Biopharm to extend the rights to L606 beyond North America to markets including Europe and Japan. The companies also signed a Device License Agreement giving Liquidia exclusive rights to Pharmosa's next-generation nebulizers for use with L606 in most countries. The filing says Liquidia will pay $3.5 million upfront and up to $157.75 million in potential milestones, with royalty terms unchanged, but it does not report any revenue or profit effect.
Upfront payment of $3.5 million due within 30 days after Liquidia Technologies receives Pharmosa's invoice following the October 2, 2024 Effective Date
Up to $7.75 million in development milestones and up to $150 million in sales milestones, both tied to activity outside North America
Pharmosa retains China, Korea, Taiwan, Middle East, North Africa, Turkey and Southeast Asia; royalties on global net sales are unchanged
Full text of the First Amendment and Device License Agreement will be filed as exhibits to the next Form 10-Q
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Liquidia filing is on SEC EDGAR ↗. 8-K briefs of other companies →